End points for Phase II trials in recurrent glioblastoma

the cornerstone for a new era.

Enrico Franceschi, Raffaele Agati, Alba A. Brandes

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In recent years, novel approaches have been developed in medical oncology, and antiangiogenic treatments have had a role in the treatment of colorectal, renal and breast cancers. The role of these agents in brain tumors is, however, controversial, since these drugs may induce modifications in neuroradiological patterns without even affecting the real tumor burden. Moreover, despite the intriguing results in terms of progression-free survival and response rate obtained with these agents, data about survival are superimposable with historical controls. Thus, there is a need for solid end points to evaluate the role of these agents in Phase II trials in the field of neuro-oncology.

Original languageEnglish
Pages (from-to)1713-1717
Number of pages5
JournalExpert Review of Anticancer Therapy
Volume11
Issue number11
Publication statusPublished - Nov 2011

Fingerprint

Medical Oncology
Kidney Neoplasms
Glioblastoma
Tumor Burden
Brain Neoplasms
Disease-Free Survival
Colorectal Neoplasms
Breast Neoplasms
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

End points for Phase II trials in recurrent glioblastoma : the cornerstone for a new era. / Franceschi, Enrico; Agati, Raffaele; Brandes, Alba A.

In: Expert Review of Anticancer Therapy, Vol. 11, No. 11, 11.2011, p. 1713-1717.

Research output: Contribution to journalArticle

@article{c930178ebb3949e7a19ab05a3b42d155,
title = "End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era.",
abstract = "In recent years, novel approaches have been developed in medical oncology, and antiangiogenic treatments have had a role in the treatment of colorectal, renal and breast cancers. The role of these agents in brain tumors is, however, controversial, since these drugs may induce modifications in neuroradiological patterns without even affecting the real tumor burden. Moreover, despite the intriguing results in terms of progression-free survival and response rate obtained with these agents, data about survival are superimposable with historical controls. Thus, there is a need for solid end points to evaluate the role of these agents in Phase II trials in the field of neuro-oncology.",
author = "Enrico Franceschi and Raffaele Agati and Brandes, {Alba A.}",
year = "2011",
month = "11",
language = "English",
volume = "11",
pages = "1713--1717",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - End points for Phase II trials in recurrent glioblastoma

T2 - the cornerstone for a new era.

AU - Franceschi, Enrico

AU - Agati, Raffaele

AU - Brandes, Alba A.

PY - 2011/11

Y1 - 2011/11

N2 - In recent years, novel approaches have been developed in medical oncology, and antiangiogenic treatments have had a role in the treatment of colorectal, renal and breast cancers. The role of these agents in brain tumors is, however, controversial, since these drugs may induce modifications in neuroradiological patterns without even affecting the real tumor burden. Moreover, despite the intriguing results in terms of progression-free survival and response rate obtained with these agents, data about survival are superimposable with historical controls. Thus, there is a need for solid end points to evaluate the role of these agents in Phase II trials in the field of neuro-oncology.

AB - In recent years, novel approaches have been developed in medical oncology, and antiangiogenic treatments have had a role in the treatment of colorectal, renal and breast cancers. The role of these agents in brain tumors is, however, controversial, since these drugs may induce modifications in neuroradiological patterns without even affecting the real tumor burden. Moreover, despite the intriguing results in terms of progression-free survival and response rate obtained with these agents, data about survival are superimposable with historical controls. Thus, there is a need for solid end points to evaluate the role of these agents in Phase II trials in the field of neuro-oncology.

UR - http://www.scopus.com/inward/record.url?scp=84858736910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858736910&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 1713

EP - 1717

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 11

ER -